1674364-87-4
1674364-87-4 結(jié)構(gòu)式
基本信息
中文別名
化合物 T15169 英文別名
DS-437DS-437 (DS437
DS-437 >=98% (HPLC)
Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-
物理化學(xué)性質(zhì)
密度1.71±0.1 g/cm3(Predicted)
儲(chǔ)存條件2-8°C
溶解度DMSO:125.0(Max Conc. mg/mL);314.5(Max Conc. mM)
酸度系數(shù)(pKa)13.13±0.70(Predicted)
形態(tài)粉末
顏色白色至米色
InChIKeyCACMCLIHCDTJHL-XNZUMOJTSA-N
SMILESNC1=NC=NC2=C1N=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](CSCCNC(NCC)=O)O3
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H301
危險(xiǎn)品運(yùn)輸編號(hào)UN 2811 6.1 / PGIII
WGK GermanyWGK 3
存儲(chǔ)類別6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects
toxic compounds or compounds which causing chronic effects
危險(xiǎn)性類別Acute Tox. 3 Oral
DS-437價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-124131 | DS-437 DS-437 | 1674364-87-4 | 5mg | 800元 |
| 2026/06/05 | HY-124131 | DS-437 DS-437 | 1674364-87-4 | 10mM * 1mLin DMSO | 880元 |
| 2026/06/05 | HY-124131 | DS-437 DS-437 | 1674364-87-4 | 10mg | 1300元 |
常見問題列表
生物活性
DS-437 是雙重蛋白精氨酸甲基轉(zhuǎn)移酶 PRMT5/7 抑制劑，對(duì)兩者的 IC50 均為 6 μM。 與其他 29 種人類蛋白質(zhì)，DNA 和 RNA 甲基轉(zhuǎn)移酶相比，DS-437 對(duì) PRMT5 和 PRMT7 具有選擇性。DS-437是 SAM 競(jìng)爭(zhēng)性抑制劑。DS-437 還抑制 DNMT3A 和 DNMT3B，IC50 分別為 52 和 62 μM。DS-437 抑制 FOXP3 的甲基化。體外研究
DS-437 was able to inhibit methylation of an H4[1–24] peptide by the PRMT5–MEP50 complex under balanced conditions (cofactor and substrate concentrations set at their respective?Km?values) in a dose-dependent manner with an IC50?of 5.9 ± 1.4 μM.
DS-437 increased total CD8
+
and CD8
+
PD-1
+
T cells.
體內(nèi)研究
DS-437 (10 mg/kg; i.p.; 5 times a week) has some beneficial effects on inhibiting tumor growth. The combination of DS-437 and the anti-p185 erbB2/neu antibody 4D5 had even more dramatic effects.
| Animal Model: | Six to Ten weeks old female Balb/c mice (bearing ?CT26Her2 tumor cells) |
| Dosage: | 10 mg/kg |
| Administration: | i.p.; 5 times a week |
| Result: | Had some beneficial effects on inhibiting tumor growth. |